Continuing Education Credits (CME, NSGC, and P.A.C.E.®)

Questions? programs@ashg.org

ASHG 2021 Virtual Meeting: October 18-22, 2021

General

If not purchased during registration, this fee can be paid by visiting the Registration Resource Center to add-on continuing education credits. You will not be able to pay for credits after the meeting.

CME Credits (AMA PRA Category 1 Credit™) $60
NSGC CEU Credits for Genetic Counselors $60
P.A.C.E.® CEUs for Laboratory Directors $60

 

The American Society of Human Genetics (ASHG) Annual Meeting is a forum for the education of physicians in the field of genetics. By attending the meeting presentations, physicians will receive both a broad overview of the field and information about the most recent, detailed research on the topic of the session. By attending any of the virtual (other) activities, physicians will better understand the basic science that underlies clinical practice.

Statement of Need

It is important that physicians comprehend the basic science that underlies clinical medicine. The American Society of Human Genetics Annual Meeting is the premier venue for this educational opportunity. Physicians, genetic counselors, laboratory geneticists, and clinical geneticists learn about the most up-to-date, cutting-edge discoveries regarding genetics.

Target Audience

This meeting is targeted to physicians, research scientists, clinical and laboratory practitioners, and others interested in the field of human genetics. The program is varied so that participants may select from several concurrent sessions, those that fit their specialized research interests and clinical practice applications.

ASHG Annual Meeting attendees include:

  • Physicians
  • Scientists/Researchers
  • Laboratory geneticists, directors, technicians, and technologists
  • Educators
  • Medical and clinical geneticists
  • Physicians of all specialties with an interest in genetics, genomics, and the genetic basis of disease
  • Genetic counselors
  • Nurses
  • Biotechnology and pharmaceutical development professionals
  • Fellows, trainees, and students

Agenda (only eligible sessions listed)

Time Session
Type
Session Title CME | P.A.C.E.® | NSGC
Tuesday, October 19
10:30am – 11:00am Plenary ASHG Presidential Address 0.50
11:00am – 12:30pm Platform Genomics in Africa coming of age 1.5
Integrate molecular and phenotype data to identify novel cancer susceptibility genes and to improve risk prediction
Mechanisms of neurodevelopmental disorders
Molecular and functional approaches to increase diagnostic rate
New approaches for single cell sequencing and analysis
Novel associations take novel statistical methods
5:30pm – 7:00pm Platform Advances toward therapeutics for Mendelian disorders 1.50
Genetic and functional insights into cardiovascular disease
Introgression and population structure in the age of genomic biobanks
Polygenic risk prediction in diverse populations: Leveraging ancestry and family history
Using mutational constraints to understand disease and improve diagnostics
When, where, and how? Insights from gene regulation – Part I
Wednesday, October 20
10:30am – 12:00pm Platform Cell-free DNA: Biological and Clinical Applications 1.50
N-of-1 Precision Medicine in the Era of Antisense Oligonucleotide Therapeutics
Novel insights into gene-environment interactions from environmental influences on Mendelian disease phenotypes
Stakeholder perspectives on ethical and social implications of using clinical polygenic risk scores through embedded ELSI research
Global genomics and health equity: Challenges and opportunities
1:00pm – 2:20pm Plenary Featured Plenary Abstract Session II 1.33
3:30pm – 5:00pm Invited Multidisciplinary omics approaches for diagnostics 1.50
Identifying repeats and structural variants underlying complex phenotypes
Cutting-edge approaches and novel gene discovery in neurodevelopmental disorders
When, where, and how? Insights from gene regulation – Part II
Leveraging large datasets to gain insights into Mendelian disease architecture
Listening to the people
5:30 – 7:00 pm Plenary Late Breaking Abstract Session 1.50
Thursday, October 21
10:30am – 12:00pm Platform Genomic insights into anthropometry and metabolic disorders 1.50
Insights into the molecular basis of craniofacial development
Insights from large-scale studies of diverse phenotypes and populations
Mechanisms of fetal CNS development
Leveraging the power of AI and electronic health records
Genetic variation in the context of immune traits
1:00pm – 2:20pm Plenary Featured Plenary Abstract Session III 1.33
3:30pm – 5:00pm Invited Technologies for optimizing impact of precision animal models for variants of uncertain significance or therapeutic development 1.50
Workforce diversity in genomics: Equity and the meaning of inclusion
Expanding the frontiers of congenital disorders of glycosylation
Cross-ancestry genomic research: Time to bridge the gap
ASHG/ESHG Building Bridges Session: Medical and evolutionary insights into human resistance against pathogens
5:30 – 7:00 pm Plenary Presidential Symposium: Perspectives on diversity, race, inclusion and equity 1.50
Friday, October 22
10:30am – 12:00pm Platform Expanding genetic approaches and applications in pharmaco- and clinical genomics 1.50
Insights into common diseases based on cross-disease studies
Unraveling the genomics of developmental and psychiatric disorders
New approaches for early detection and prognosis of cancer
Mechanisms underlying identification and transcriptional control of mitochondrial and related disorders
Omic disease dissection in diverse populations
1:00pm – 2:20pm Plenary Featured Plenary Session IV 1.33
3:30pm – 5:00pm Invited Nonsense-mediated decay: A double-edged sword in cancer and genetic diseases 1.50
Gatekeeping genetics: Towards a more diverse, just, and inclusive research enterprise
Global resources for precision medicine research
Total
19.50

 

Learning Objectives:

  • Describe the latest advances in the field of human genetics and genomics research.
  • Illustrate novel genetic findings from large population and clinical cohorts.
  • Describe computational modeling approaches for analysis of large genomic datasets to gain new functional insights.
  • Identify cutting edge pharmacogenetic research in racially/ethnically diverse populations.
  • Evaluate the effectiveness of disease modeling for understanding the genetic basis of disease.
  • Contrast the methods used to identify rare and common variants that predispose to cancer.
  • Describe current and emerging technologies for studying genetic and genomic variation.
  • Discuss the ways in which the field of human genetics acts as a gatekeeper to diversity, equity, and inclusion.
  • Define the methods used to generate high quality whole genome sequencing data.
  • Discuss possible mechanisms that are shedding new light on how environmental exposures and other environmental risk factors impact Mendelian disease outcomes, which is a significantly understudied area in the human genetics field.
  • Illustrate the potential utility and accuracy of using whole genome sequencing as a first line test in patients with a suspected genetic diagnosis.
  • Identify how workforce diversity is conceptualized in genomics.
  • Explain advances in the diagnosis of mitochondrial disorders.
  • Identify the challenges of polygenic risk prediction in diverse populations.
  • Illustrate genetic and genomic approaches to study immune traits.
  • Compare reasons why people participate in genetic research or pursue genetic testing across populations.

Presenters

To see the session presenters, please visit the online program planner.

Disclosures

Speaker and moderator disclosures coming soon.

Continuing Medical Education Credits (CMEs)*

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine (PIM) and the American Society of Human Genetics. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

PIM designates this other (virtual events) activity for a maximum of 19.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE (Continuing Education for non-physicians): This activity has been approved for CE credits.
*The certificate is accepted by the ABMGG for certification.

Procedures

Application details will be available in early October.

There is a nonrefundable $60 fee payable during the registration process. If not purchased during registration, this fee can be paid by visiting the Registration Resource Center. You can apply for credits through the online application available beginning Tuesday, October 19, 2021. The deadline to submit your request is Friday, December 3, 2021.

Continuing Education Unit Credits (CEUs) for Genetic Counselors

Credit Designation

This event will be submitted to the National Society of Genetic Counselors (NSGC) for approval of Category 1 CEUs. The American Board of Genetic Counseling (ABGC) accepts CEUs approved by NSGC for purposes of recertification.

Procedures

Application details will be available in early October.

There is a nonrefundable $60 fee payable during the registration process. If not purchased during registration, this fee can be paid by visiting the Registration Resource Center. You can apply for credits through the online application available beginning Tuesday, October 19, 2021. The deadline to submit your request is Friday, December 3, 2021. NSGC User IDs are required for all participants wishing to claim CEUs. Please use these instructions to find or create your NSGC User ID.

Genetic Counselors and Nurses should apply for CEUs. The American Board of Genetic Counseling (ABGC) will accept CEUs earned at this program for the purposes of certification and recertification.

The CEU fee of $25 per participant is paid to the National Society of Genetic Counselors for the filing and awarding of CEU certificates. This is included in the $60 fee paid and also covers staff and administrative costs.

Continuing Education Unit Credits (CEUs) for California-Licensed Clinical and Molecular Laboratory Directors (P.A.C.E.®)

Credit Designation

This program has been submitted to The Commission for Case Manager Certification for approval to provide board certified case managers with 19.50 clock hour(s).

Procedures

Application details will be available in early October.

There is a nonrefundable $60 fee payable during the registration process. If not purchased during registration, this fee can be paid by visiting the Registration Resource Center. You can apply for credits through the online application available beginning Tuesday, October 19, 2021. The deadline to submit your request is Friday, December 3, 2021.

Clinical Laboratory Scientists should apply for P.A.C.E. CEUs. ABMGG will accept P.A.C.E. CEUs for diplomats participating in the MOC program in the following categories: Clinical Biochemical Geneticist, Clinical Cytogeneticist, and Clinical Molecular Geneticist.

ASHG CME Policies and Procedures

As a joint provider with the Postgraduate Institute for Medicine (PIM) accredited by the Accreditation Council for Continuing Medical Education (ACCME), the American Society of Human Genetics plans and implements all of its educational activities in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education and to ensure balance, independence, objectivity and scientific rigor. In accordance with the ACCME® Standards for Integrity and Independence, everyone (speakers, moderators, platform presenters, all authors, committee members, and staff) who is in a position to control the content of an educational activity certified for AMA PRA Category 1 Credit is required to disclose all financial relationships with any commercial interests (see definition below) within the past 24 months that creates a real or apparent conflict of interest. Individuals who do not disclose are disqualified from participating in a CME activity. 

Individuals with potential for influence or control of CME content include:

  • planners, planning committee members, staff
  • authors
  • others who participate, e.g., facilitators and moderators

This disclosure pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services, which are used on or directed to patients, may be related to the subject matter of the presentation topic. Any real or apparent conflicts of interest related to the content of the presentations must be resolved prior to the educational activity. Disclosure of off-label, experimental or investigational use of drugs or devices must also be made known to the audience. 

ASHG’s Policy and Procedure for Identifying and Resolving Conflict of Interest for CME Educational Activities

The ACCME Standards of Commercial Support (SCS) describe six Standards:  

(1) independence 
(2) resolution of personal conflicts of interest 
(3) appropriate use of commercial support
(4) appropriate management of associated commercial promotion 
(5) content and format without commercial bias and 
(6) disclosures relevant to potential commercial bias.  

These updated Standards underscore continued voluntary self-regulation by the CME community, ensuring that physicians have opportunities to engage in commercially unbiased life-long learning facilitated by accredited providers.  

The purpose of this policy is twofold:  

[1] to establish guidelines and a mechanism for identifying and resolving conflicts of interest in CME educational activities as required in Standard 2 (see below), and 
[2] to be consistent with ASHG’s policy for resolving conflicts of commitment and interest. Regardless of role, disclosure forms for speakers, moderators, all authors, program committee and staff participating in a CME activity will be collected and reviewed. 

Standard 2: Resolution of Personal Conflicts of Interest in the Standards for Commercial Support requires the following of ACCME accredited providers – 

  • Documenting that everyone who is in a position to control the content of an education activity has disclosed to the provider all relevant financial relationships with any commercial interests in any amount within the past 12 months that creates a conflict of interest. (SCS 2.1)
  • Disqualifying individuals who do not disclose from participating in a CME education activity. (SCS 2.2)
  • Identifying and resolving all conflicts of interest prior to the education activity. (SCS 2.3)

Terms as Defined by the ACCME:

  1. Ineligible Company: Those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
  2. Conflict of Interest: The ACCME considers financial relationships to create conflicts of interest in CME when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest. The potential for maintaining or increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the CME – an incentive to insert commercial bias. See also “relevant financial relationships.”
  3. Financial Relationship: The ACCME requires anyone in control of CME content to disclose relevant financial relationships to the accredited provider. The ACCME has not set a minimal dollar amount—any amount, regardless of how small, creates the incentive to maintain or increase the value of the relationship. Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria for promotional speakers’ bureau, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. See also “conflict of interest.”
  4. Individuals with potential for influence or control of CME content: Planners and planning committee members, authors, teachers, educational activity director(s), educational partners(s), and others who participate, e.g. facilitators and moderators.

Please note: The ACCME has not a minimum dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.

ASHG’s Procedures to Identify/Resolve Conflict:

  • All individuals with potential for influence or control of content (defined in #2 above) must complete an ASHG’s Disclosure Form prior to the education activity as a condition of invitation and acceptance to participate. ASHG staff and Program Committee members are also required to complete an annual disclosure form.
  • An independent and unbiased assessment of content will be documented by one of the following methods to identify and resolve COIs –
    • Content review by the program planning committee.
    • Peer review committee are not participating in the specific educational activity.
    • Disclosures of all individuals participating in the educational activity will be made known to the audience as required by the ACCME, in addition to a disclosure of any COIs that have been resolved with independence and without bias.
    • Speakers will be required to verbally and include a disclosure slide (1st slide) identifying commercial relationships/interests or if none. Additionally, they must inform the audience prior to the presentation of any discussion of off-label use.

Consequences of non-adherence to the ASHG’s policy consists of:

  • Disqualified from speaking if no disclosure form is completed (SCS 2.2)
  • Warning letter if the activity evaluation by the audience and session monitor comments indicates conflicts are present (1st occurrence)
  • Not invited to speak or participate in any other role in a ASHG CME-certified educational activity (2nd occurrence)

Content Validation and Fair Balance

  1. ASHG follows the ACCME policy on Content Validation for CME activities, which requires:
    1. All recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients.
    2. All scientific research referred to, reported, or used in CME in support or justification of patient care recommendations must conform to the generally accepted standards of experimental design, data collection, and analysis.
  2. Activities that fall outside the definition of CME/CE, “Educational activities that serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession” (source: ACCME and AMA), will not be certified for credit. CME activities that promote recommendations, treatment, or manners of practicing medicine or pharmacy that are not within the definition of CME/CE or, are known to have risks or dangers that outweigh the benefits or, are known to be ineffective in the treatment of patients.
  3. Presentations and CME/CE activity materials must give a balanced view of therapeutic options; use of generic names will contribute to this impartiality. If the CME/CE educational materials or content includes trade names, where available, trade names from several companies must be used.

Off-Label or Unapproved Use of Drugs or Devices

In accordance with the ACCME, ASHG and PIM ensures that all content is fair, balanced and represented with this highest integrity. All recommended off-label or unapproved uses of drugs are either properly cited or the recommendation is clearly marked as the speakers opinion.

It is the policy of the ASHG to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) and the policy of the American Society of Human Genetics (ASHG), speakers and moderators presenting in sessions that offer CME and CEU credit must disclose, prior to the start of their presentations, the existence of any relevant financial interest and/or other relationship(s) they might have with the manufacturer(s) or provider(s) of any commercial product(s) or service(s), including diagnostic laboratories to be discussed during their presentation. These disclosures are included in the Online Program Planner.

All speakers are required to provide a slide that states any relevant financial relationships (or lack thereof), and to state these to the audience at the start of their presentation. All disclosures have been peer reviewed by the ASHG Program subcommittee and PIM content review team.

Diagnostic and Testing Labs and Commercial Interest

ASHG CME activities adhere to the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. The ACCME has defined under its conflict of interest definition the types of industry interests that must be excluded from CME content delivery. This largely applies to manufacturers of pharmaceuticals and devices. Diagnostic laboratories, whether not-for-profit or for-profit, that are not owned by device manufacturers are exempted from this CME requirement. However, they are still expected to be fair and balanced in their presentations.

HIPAA Compliance by Speakers

The ASHG supports medical information privacy. While the ASHG is not a “covered entity” under HIPAA 1996 and therefore is not required to meet these standards, ASHG wishes to take reasonable steps to ensure that the presentation of individually identifiable health information at ASHG-sponsored events has been properly authorized. All presenters have completed a form indicating whether they intend to present any form of individually identifiable healthcare information. If so, they were asked either to attest that a HIPAA-compliant consent form is on file at their institution, or to send ASHG a copy of the HIPAA compliance form. This information is on record at the ASHG Administrative Office and will be made available upon request.

Disclaimer

The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of ASHG.

This program has been submitted to The Commission for Case Manager Certification for approval to provide board certified case managers with 19.50 clock hour(s).

ACCME Accreditation Requirements and Guidelines

All speakers/authors must sign a disclosure statement regarding the existence of any relevant financial interest and/or other relationship(s) they and/or their spouse/legally recognized domestic partner might have with the manufacturer(s) or provider(s) of any commercial product(s) or service(s) or with commercial and academic laboratories that accept samples for testing or develop any laboratory test or test(s) to be discussed during their presentations.

The content or format of a CME activity or its related materials must promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity. Presentations must give a balanced view of therapeutic options. Use of generic names will contribute to this impartiality. If the educational material or content includes trade names, trade names from several companies should be used when available, not just trade names from a single company.

Authors/speakers must adhere to these guidelines as outlined below. Failure to do so may result in your presentation being excluded from the meeting.

  • For authors/speakers of abstracts, the disclosure information completed during abstract submission will be used automatically.
  • For speakers in invited sessions and invited workshops, you will be contacted by ASHG staff to complete a disclosure statement.
  • Disclosure of financial relationships will be listed on our website.
  • Conflicts that may affect the content of presentations will be required to provide a copy of their slides in advance of the meeting so they can be peer-reviewed.
  • Authors/speakers must not engage in the marketing of product(s) in any way during the presentation.
  • Talks must be free of commercial bias for or against any product. If commercial products are discussed, the session must present objective information about those products, based on generally accepted scientific evidence.
  • Presentation Slides
    • To satisfy potential conflict-of-interest requirements, there are constraints regarding the use of any logos on presentation slides. The constraints include no logos on each slide.
    • Authors who disclosed a conflict may be contacted and asked to upload their slides in advance of the meeting so that the slides can be reviewed by members of the Program Committee. Once approved, the slides cannot be changed.
    • Authors/speakers must include a conflict-of-interest slide as part of their presentations to meet ACCME requirements, even when there is nothing to disclose. This ASHG-approved slide must be inserted as the first slide in the presentation.

 

Questions?

Contact ASHG

ASHG uses cookies to provide you with a secure and custom web experience. Privacy Policy